Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
$18.0379
0.53(2.9%)
as of November 3, 2025
Try our APIs with
free plan!
Summit Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Prev. Close
18.0379
Open
18.5669
High
19.0314
Low
18.0284
52 wk Range
15.55-36.91
Market Cap
13 564 M
Shares Outstanding
744 M
EPS
-0.2315
Beta
-1.547
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Summit Therapeutics PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -934 987 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: -0.1032
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News
New
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See
When looking for a clear market signal pointing toward the right stocks to buy, insiders’ trading activity remains a potent one. Elevate Your Investing Strategy: Take advantage of TipRanks Premiu...
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen MIAMI, October 31, 2025--(BUSINESS WIRE)--Su...
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Stocks to Buy with Exponential Growth Heading into 2026.On October 20, the company released its financial results and gave an update on operationa...
Insiders Are Buying These 3 Stocks Hand Over Fist
vectorfusionart / Shutterstock.com Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that ins...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
